Category:
Keywords:

Handbook of Pediatric Electroencephalography by Veena Kander now on ICNApedia VLE

Lacosamide

Hot
 
0.0 (0)
21030   0
Write Review
Unbalanced scales This only describes one highly specialized aspect of its associated subject.
Please help improve this article by adding more general information.
Please see the discussion on the comments pages
Print Friendly and PDF

Lacosamide is a functionalized amino acid (R)-2-acetamido-N-benzyl-3-methoxypropionamide. It is one of the latest AEDs to be licensed (at the end of 2008), under the brand name Vimpat.

Contents[Hide]

Authorised indications

SmPC: adjunctive therapy in the treatment of focal seizures with or without secondary generalisation in patients with epilepsy aged 16 years and older. Solution for infusion is an alternative for patients for whom oral administration is temporarily not feasible.

FDA: (1) tablets are indicated as adjunctive therapy in the treatment of focal seizures in patients with epilepsy aged 17 years and older and (2) injection for intravenous use is indicated as adjunctive therapy in the treatment of focal seizures in patients with epilepsy aged 17 years and older when oral administration is temporarily not feasible.

Clinical applications

Based on RCTs, lacosamide is a useful addition to our armamentarium in the treatment of epilepsy. This is also supported by experience since its introduction in clinical practice.

Lacosamide has proven efficacy and a high retention rate (77% in a year) in difficult to treat patients. It is particularly important in adjunctive AED therapy because of its excellent pharmacokinetic profile, minimal drug to drug interactions, good safety and novel mechanism/s of action, which is different than any other AED co-medication. It is considered as having less sedative effects than most other AEDs. Intravenous solution is important when oral drug administration is impossible.

Dosage and titration

“Start low and go slow”

Adults: Start with 50 mg twice daily (100 mg/day). Increase at weekly intervals by 100 mg/day to 200–400 mg/day.

The maximum recommended dose of lacosamide is 400 mg/day because higher doses may be associated with CNS and gastrointestinal ADRs.

A maximum dose of 300 mg/day is recommended by the FDA for patients with mild or moderate hepatic impairment; no such upper limits are recommended by the EMEA.

Lacosamide injection (without further dilution or mixed in compatible diluents) should be administered intravenously over 15–60 minutes. When switching from oral lacosamide, the initial total daily intravenous dosage should be equivalent to the total daily dosage and frequency of oral lacosamide. When used as shortterm replacement for oral lacosamide, intravenous lacosamide was well tolerated when administered as a 15-, 30- or 60-minute infusion.

Dosing: twice daily

TDM: unknown.

Reference range: unknown.

Main ADRs

Frequent and/or important: Dizziness, headache, diplopia, nausea, vomiting and blurred vision.

Serious: A small, asymptomatic, dose-related increase in the PR interval measured on ECG has been observed in clinical studies (see also eslicarbazepine ). However, atrioventricular block is uncommon, with an occurrrence of 0.7%, 0%, 0.5% and 0% for lacosamide 200 mg, 400 mg, 600 mg or placebo, respectively. No second or higher degree atrioventricular block was seen in lacosamide patients. Also, the incidence rate for syncope did not differ between lacosamide (0.1%) and placebo treated epilepsy patients (0.3%). However, caution is needed in patients with known conduction problems or severe cardiac disease, in the elderly and in comedication with drugs known to be associated with PR prolongation (e.g. carbamazepine, lamotrigine, pregabalin, eslicarbazepine or class I antiarrhythmic drugs), though an increased magnitude of PR prolongation has not been found so far in comedication with carbamazepine or lamotrigine.

Considerations in women

Pregnancy: category C. Breastfeeding: unknown but possibly excreted in breast milk (animal data). Interactions with hormonal contraception: none.

Main mechanisms of action

Not fully elucidated but two mechanisms are possible: (a) lacosamide selectively enhances slow inactivation of voltage-gated sodium channels, resulting in stabilization of hyperexcitable neuronal membranes and inhibition of repetitive neuronal firing (Figure 1) and (b) lacosamide may bind to collapsin response mediator protein–2 (CRMP–2), a phosphoprotein which is mainly expressed in the nervous system and is involved in neuronal differentiation and control of axonal outgrowth. The role of CRMP-2 binding in seizure control is unknown.

lacosamide

Pharmacokinetics

Lacosamide has near-ideal pharmacokinetics (score 96 out of maximal best 100).

Oral bioavailability: 100%.

Protein binding: <15%

Metabolism: Primarily eliminated by renal excretion and biotransformation. Its metabolism has not been fully elucidated but CYP-2C19 is involved in the demethylation of lacosamide. Lacosamide showed no potential to induce or inhibit the activity of CYP isoforms 1A1, 1A2, 2A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1 and 3A4 in human hepatocytes at therapeutic concentrations, although inhibition of the CYP2C19 iso-enzyme was noted at concentrations 15-times higher than therapeutic concentrations.

Elimination half-life: ours.

Drug interactions

These are minimal and probably of no clinical significance. From available evidence, lacosamide does not affect plasma levels of carbamazepine or its epoxide metabolite, gabapentin, lamotrigine, levetiracetam, oxcarbazepine, phenytoin, topiramate, valproate and zonisamide or the oral contraceptive levonorgestrel/ethinylestradiol, metformin and digoxin.1 Carbamazepine, phenytoin and phenobarbital may decrease plasma levels of lacosamide by 15–20%. Omeprazole (a CYP2C19 inhibitor) did not produce any clinically significant changes in lacosamide plasma concentrations.

Main disadvantages

Not yet exposed to lengthy clinical practice but its use so far has met with favourable results.

References

  1. Beydoun A, D’Souza J, Hebert D, Doty P. Lacosamide: pharmacology, mechanisms of action and pooled efficacy and safety data in partialonset seizures. Expert Rev Neurother 2009;9:33-42.

quickbrownfoxappleorangesjumpedover

http://icnapedia.org/wiki/drugs-in-neurology/lacosamide
APA Style
Lacosamide. (n.d.). In ICNApedia. Retrieved May 23,2017 15:28:27 from http://icnapedia.org/wiki/drugs-in-neurology/lacosamide
MLA Style
"Lacosamide." ICNApedia: The Child Neurology Knowledge Environment, Inc. November 02, 2015. Web. May 23,2017 15:28:27
AMA Style
ICNApedia contributors. Lacosamide. ICNApedia, The Child Neurology Knowledge Environment. November 02, 2015. Available at: http://icnapedia.org/wiki/drugs-in-neurology/lacosamide.Accessed May 23,2017 15:28:27.

Reader reviews

No readers have reviewed this article yet
Already have an account?
Ratings (the higher the better)
Trustworthiness
Has this page got sufficient citations and have they come from trustworthy sources
Completeness
Does this article cover the topic area adequately
Well written
Is the article well organized and well written
Comments
You will be able to upload media right after you submit your review.